TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT

The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	STROBL Stefan, RÖSEMANN Roman, SAHIN Ugur, HASSAN Hariz Iskandar Bin
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer. La presente divulgación se relaciona con el agonista de TLR7 específico BNT411, como composiciones y kits que comprenden BNT411, y al uso de BNT411 como agente inmunoterapéutico en monoterapia y terapia combinada para reducir o prevenir la progresión de un tumor, en particular un tumor sólido, o tratar el cáncer, en particular un cáncer sólido.